Gestational diabetes mellitus (GDM), a high-risk pregnancy complication of great effect on the perinatal health of women and newborns, may cause changes of gut microbiota in mothers and further affect gut microbiota in newborns. This study aimed to investigate the potential effect of mother GDM on newborns’ gut microbiota. Meconium DNA was extracted from a total of 34 full-term and C-sectioned newborns, in which 20 newborns had mothers diagnosed with GDM, while 14 had unaffected mothers. Sequencing and bioinformatics analysis of 16S rRNA indicated that the gut microbiota of GDM newborns showed differences compared to control newborns. The taxonomy analyses suggested that the overall bacterial content significantly differed by maternal diabetes status, with the microbiome of the GDM group showing lower alpha-diversity than that of control group. The phyla of Proteobacteria and Actinobacteria in GDM newborns increased, while that of Bacteroidetes significantly reduced (P<0.05). Moreover, several unique gut microbiota in phylum of Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes, Chloroflexi, Acidobacteria, and Planctomycetes found in control newborns were absent in GDM ones. At genus level, the relative abundance of Prevotella and Lactobacillus significantly decreased (P<0.05) in GDM newborns. Correlation analysis indicated that maternal fasting glucose levels were positively correlated with the relative abundance of phylum Actinobacteria and genus Acinetobacter, while negatively correlated with that of phylum Bacteroidetes and genus Prevotella. However, bacteria in GDM grade A2 (GDM_A2) newborns did not show any statistical variation compared to those from control newborns, which might be attributed to the additional intervention by insulin. The results of this study have important implications for understanding the potential effects of GDM on the gut microbiota of newborns and thus possibly their metabolism at later stages in their lives.
Citation: Su M, Nie Y, Shao R, Duan S, Jiang Y, Wang M, et al. (2018) Diversified gut microbiota in newborns of mothers with gestational diabetes mellitus. PLoS ONE 13(10): e0205695. https://doi.org/10.1371/journal.pone.0205695
Editor: Gianfranco D. Alpini, Texas A&M University, UNITED STATES
Received: April 14, 2018; Accepted: September 28, 2018; Published: October 17, 2018
Copyright: © 2018 Su et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information file.
Funding: This work was funded by National-level College Students’ Innovative Training Plan (201710611767), SR received the funding, and National Key Research and Development Plan: Prevention of the pregnancy complications of women greater than or equal to 35 years old (2016YFC1000400), XW received the funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Gestational diabetes mellitus (GDM) is an asymptomatic disorder characterized by carbohydrate intolerance, which appears to be normal for glucose metabolism before pregnancy, but leading to diabetes during pregnancy . Because of its high incidence and great influence on mothers and infants, GDM has attracted wide attention worldwide. With the increase of obesity and type 2 diabetes, GDM has increased significantly in recent years. In accordance with epidemiological surveys conducted in China, the incidence of GDM has increased by nearly 3 times, from 2.4% in 1999 to 6.8% in 2008 , further reaching 9.3% in 2012 . GDM-affected pregnancies are considered as high-risk, as they are associated with increased risk of preeclampsia, preterm birth and other adverse short term pregnancy outcomes . Long term complications for GDM mothers include increased risk of type 2 diabetes (T2D) and cardiovascular diseases [5, 6]. Additionally, GDM not only increases the risk of adverse pregnancy outcomes in mothers, but also increases the risk of short- and long-term complications in newborns, such as neonatal malformations  and neonatal obesity . Moreover, GDM induces long-term neurological defects in infants, which become more pronounced in childhood , characterized by attention deficit, lower level of cognition, compromised movement ability or linguistic competence .
The foetal gut was thought to be sterile, but existing studies show that bacteria are present in the gut before birth . Early life is the critical period for colonization and maturation of gut microbiota, which can influence the maturation of the newborn's immune system [12, 13], and subsequent development of diseases, such as asthma  and obesity [15–17]. The intestinal microbiota in early life is susceptible to the influence of maternal factors, delivery mode  and postnatal factors. Studies have shown that the bacterial composition of the maternal gut could affect (both qualitatively and quantitatively) the bacterial content of infant meconium , and another investigation also indicated that the placental microbiome profiles were most akin to the nonpregnant human oral microbiome . A previous study has also confirmed that GDM is capable of causing gut microbiota dysbiosis and functional changes in the mother's intestine , compared with healthy pregnant women. Accordingly, we hypothesized that gut microbiota from the offspring of mothers with GDM may change and may have impact on the health of offspring. The aim of this study was to investigate the potential correlation between maternal GDM and foetal gut microbiota by exploring the distribution of the dominant microbes in infants.
Materials and methods
The present study conforms to the principles outlined in the Declaration of Helsinki. This study was approved by the West China Second Hospital Review Board of Sichuan University, Chengdu, China. All patients provided written informed consent prior to participation in the study protocol.
Study population and sample collection
This study was performed on normal full-term newborns born with caesarean section in West China Second Hospital of Sichuan University from August 31, 2016 to January 10, 2017, and whose mothers provided informed consents. The inclusion criteria were: 1) pregnant women whose gestational age was 37 to 42 weeks and eventually underwent caesarean section; 2) pregnant women who had regular prenatal visits and all clinical information could be obtained; 3) pregnant women with GDM or without GDM. 4) The newborns were full-term. The exclusion criteria were: 1) any infection occurring during pregnancy, especially gastrointestinal or genital tract infections; 2) pregnant women using any type of antibiotic during pregnancy, excluding the antibiotic administered before caesarean section as standard obstetric care; 3) pregnant women with any other complications, such as mental disorder, hypertension, preeclampsia, eclampsia; 4) newborns administrated any type of antibiotic after birth; 5) women who eventually underwent C-section and received an immediate dose of Kefzol (cefazolin) 30 mins prior to C-section as a standard of care were retained in the study; 6) obstetric risks, such as HIV positive, significant congenital anomalies, neurological dysfunction, foetal chromosomal anomalies, or inborn metabolic disorders. The following maternal clinical information was collected: mother's age at childbirth; oral glucose tolerance test in the second trimester (fasting, one hour postprandial, two hours postprandial); whether there was a diagnosis of GDM; whether diabetes was diagnosed before pregnancy; treatment measures for diabetic gravidae; pre-delivery weight; pre-pregnancy and prenatal BMI; gestational weight gain; pregnancy history; gestational age at delivery; delivery mode. Collected infants’ clinical information included sex, weight and height. The personal information was recorded on the infusion label, including the name of the expectant mother, the date of delivery, the registration number, the bed number. The label was attached to the medical waste bags that were distributed to the participants. The samples were taken by collecting the newborn’s diapers with faeces using bags within 24 hours after birth. The meconium was scraped with a disposable blade, collected into 1.5 mL sterilized centrifuge tubes in the examination room and stored at -80°C immediately for later use.
Faecal DNA extraction
QIAamp DNA Stool Mini Kits (QIAGEN) were used to extract the total DNA of microorganisms in 200 mg of each faecal sample, according to the suggested specific operating procedures recommended by the QIAamp DNA Stool Handbook. DNA concentration was determined with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). The extracted DNA was stored at −20°C until further analysis.
Meconium microbiome profiles were assessed by 16S rRNA gene amplicon sequencing using the Illumina MiSeq system (Illumina, San Diego, CA, USA). The V4 variable regions of bacterial 16S rRNA genes were PCR amplified from genomic DNA using the primers 515F (5’-GTG CCA GCM GCC GCG GTA A -3’) and 909R (5’-CCC CGY CAA TTC MTT TRA GT -3’) . The PCR mixture (25 μL) contained 1× PCR buffer, 1.5 mM MgCl2, each deoxynucleotide triphosphate at 0.4 μM, each primer at 1.0 μM and 0.5 U of Ex Taq (TaKaRa, Dalian) and 10 ng faecal genomic DNA. The PCR amplification program included initial denaturation at 94°C for 3 min, followed by 30 cycles at 94°C for 40 s, 56°C for 60 s, and 72°C for 60 s, and a final extension at 72°C for 10 min. We conducted two PCR reactions for each sample, and combined them together after PCR amplification. PCR products were detected by 1% of agarose gel electrophoresis, purified using the Gel Extraction Kit (Sangon Biotech, Shanghai), determined with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies), and finally submitted to Biobit Biotech Inc. (Chengdu, China) for Illumina paired-end library preparation, cluster generation, and 250-bp paired-end sequencing on an Illumina MiSeq instrument in two separate runs.
Raw Illumina fastq files were demultiplexed, in which the paired-end sequences were merged as raw tags using FLASH (Fast Length Adjustment of Short reads) v1.2.7. Then, these raw tags were strictly quality filtered and analysed using QIIME (Quantitative Insights into Microbial Ecology) v1.9.0. Reads were truncated at any site containing more than three consecutive bases receiving a quality score <1e-5, and any read containing one or more ambiguous base calls was discarded. Operational taxonomic units (OTUs) were assigned using QIIME’s uclust-based open-reference OTU-picking workflow, with a threshold of 97% pairwise identity. Sequences were mapped, yielding an OTU table, and a phylogenetic tree was constructed using FastTree , which was then used to generate unweighted and weighted UniFrac distance metrics. Any OTUs with overall relative abundance <1e-4 were excluded from further analysis.
Comparisons between the control and GDM group were performed using student t test and Mann-Whitney test. Statistical analysis of the clinical data was performed using SPSS (Statistic Package for Social Science) 17.0 software (SPSS Inc., Chicago, IL, USA). P<0.05 was considered statistically significant. The gut microbiota diversity within samples from each individual (α-diversity) was assessed by the Shannon index, Simpson index, Chao1 richness index and Observed Species. Significant differences in microbial community composition between the control and GDM group (β-diversity) were calculated by permutational MANOVA (pMANOVA) of weighted UniFrac distances (Bray-Curtis distance method) [24, 25] with 999 permutations and illustrated by principal coordinates analysis (PCoA). Associations between maternal clinical index and gut microbiota in meconium samples of newborns were evaluated by bootstrapped Spearman rank correlation coefficient using 1,000 permutations.
In this study, the diagnostic criteria for GDM were based on the GDM diagnostic recommendations of the International Association of Diabetes and Pregnancy Study Groups (IADPSG) , and included the 75 g Oral Glucose Tolerance Test (OGTT), fasting, 1 hour and 2 hours post prandial blood glucose values of 5.1 mmol/L, 10 mmol/L, and 8.5 mmol/L, respectively. Any of the above-mentioned blood glucose levels that meet or exceed the diagnostic criteria leads to the diagnosis of GDM. The GDM staging criteria were based on the White classification method . The clinical characteristics of pregnant women and their newborns included in this study are presented in Table 1. A total of 34 newborns were included in the trial, with 20 newborns whose mothers were diagnosed with GDM. Fifteen mothers were diagnosed as GDM grade A1 (GDM_A1) and 5 mothers were diagnosed as GDM grade A2 (GDM_A2). Exercise and diet control were used to treat pregnant women with GDM. Pregnant women with GDM grade A2 were additionally treated with insulin administration. Fourteen newborns from non-GDM mothers were used as the control group. All the newborns included were born by caesarean section, and their neonatal Apgar scores for 1 min, 5 min and 10 min were all 10.
There were significant differences (P<0.05) in fasting, 1 hour and 2 hours of blood glucose values between the two groups (Table 1), with GDM mothers having a higher OGTT index. No significant difference was observed in age, gestational age at delivery, antepartum weight, gestational weight gain, pre-pregnancy BMI and antepartum BMI of mothers between control, GDM_A1 and GDM_A2 groups (P>0.05, t-test). The newborn weight and height at birth did not differ significantly among the three groups (P>0.05, t-test). There was a higher percentage of male newborns in the GDM_A1 group (male/female = 2.75).
Overview of gut bacterial diversities in the GDM newborns and the control newborn subjects
Rarefaction curve can be used to compare the abundance of species in samples with different numbers of sequences, and to indicate whether the sampling size (sequencing depth) is reasonable. When the curve tends to be flat, it indicates that the number of samples is reasonable, and more samples will produce only a small amount of new OTU. Conversely, more new OTU may be generated by continuing the sampling. According to the Figure A in S1 File, 10,357 sequences per sample of sequencing depth was reasonable.
The parameters of Shannon index, Simpson index, Chao1 index and Observed species index were used to assess the overall diversity thoroughly. The alpha-diversity, which is the mean species diversity in gut, showed that the gut microbiota from the GDM groups were different to some extent compared to the control group. The Simpson index was used to measure the degree of concentration when individuals were classified into types, and the Shannon index was used to quantify the uncertainty . However, there were no significant differences among the groups in terms of the Shannon and Simpson indexes (Fig 1A and 1B, Wilcoxon test, P>0.05). The Chao1 index in the GDM_A1 and GDM_Total group was statistically lower than that in the control group (Fig 1C, Wilcoxon test, P<0.05), but the index for the GDM_A2 group was moderately (P>0.05) lower than that in the control group. For total number of species, the Observed species index of the control group was moderately higher than that GDM group (Fig 1D, Wilcoxon test, P>0.05). These results showed that the number of gut bacteria in the control group was higher than that in GDM group, and there were a large number of dominant bacteria and lower distribution uniformity of bacteria in the GDM group compared to the control group. The number of intestinal bacteria in the GDM group decreased compared with the control group, while the distribution uniformity increased, indicating that some dominant populations were decreasing, especially in GDM grade A1.
The groups of control (n=14), GDM_A1 (n=15), GDM_A2 (n=5) and GDM_Total (n=A1+A2=20) were described in the Methods. (A, B) The ecological diversity of gut microbiota in the control and GDM groups was measured by Shannon index and Simpson index. (C, D) The alpha-diversity, richness of gut microbiota, was determined by Chao1 index and Observed species index.
The results of Weighted UniFrac diversity analysis and PCoA are shown in Fig 2, and indicate that the gut microbial communities were different between the control and GDM groups. The distribution of the control group was more scattered, and the distance between samples was longer than that in GDM group, indicating that individual differences were larger in the control group, and evolutionary similarities of gut microbiota were small and the differences were larger compared with the GDM group (Fig 2A). The two GDM groups had significantly greater PCA variation than that in the control group (Fig 2B, Wilcoxon test, P<0.05, P<0.01).
(A) Principal Coordinates Analysis (PCoA) plot based on weighted UniFrac distance. Each dot represents one sample from each group. (B) Beta-diversity index difference based on weighted UniFrac. The P-values were calculated using Wilcoxon test. Statistical significance is displayed as * P < 0.05 and ** P < 0.01.
The bacteria differ significantly between the control and GDM groups
We calculated the number and relative abundance of all species at phylum and genus level among different samples (Fig 3). According to the phylum level, the control and GDM groups both had three phyla of Archaea, and there were 50 and 39 phyla of Bacteria in the control and GDM groups, respectively, showing that more than 90% of species belonged to Bacteria. Bacteria belonging to the phyla of Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes, Synergistetes, Thermi, Spirochaetes, Chloroflexi and Euryarchaeota were the main gut microbiota in all samples (Fig 4), in which the phyla Proteobacteria was the most prominent of gut microbiota with more than 45% of the total abundance and containing many Gram-negative bacteria and opportunistic pathogenic species. Compared with the control group, relative abundance of Proteobacteria in GDM groups moderately increased, while the Actinobacteria in GDM groups were significantly increased (P<0.05, P<0.01). Importantly, the phylum Bacteroidetes, which contains many beneficial organisms, was significantly decreased in the GDM_A1 group in comparison with the control group, while the GDM_A2 group had almost no variation. Additionally, the relative abundance of Firmicutes, Synergistetes, Thermi, Spirochaetes, Chloroflexi and Euryarchaeota from the GDM group seemingly decreased compared with that from the control group, however, the decrease did not show any statistical difference between the two groups (P>0.05).
(A) Bacterial phylum levels of each sample in the groups of control, GDM_A1 and GDM_A2 respectively. (B) Bacterial phylum average levels of each group. (C) Bacterial genus levels of each sample in the groups of control, GDM_A1 and GDM_A2 respectively. (D) Bacterial genus average levels of each group.
The P-values were calculated using Mann-Whitney test, and significance was compared against the control group. *P < 0.05. **P < 0.01.
Additionally, to understand the difference of gut microbiota at bacterial taxonomic levels of class, order and family, we calculated the amount of gut microbiota between GDM and control group in the main phyla (Figure B in S1 File). Compared with the control group, the amount of gut microbiota at level of class in GDM group significantly decreased in the phyla of Acidobacteria, Chloroflexi and Planctomycetes (P<0.05), and the amount of gut microbiota at level of order and family in GDM group significantly decreased in the phyla of Proteobacteria, Firmicutes, Acidobacteria, Chloroflexi and Planctomycetes (P<0.05).
The higher relative abundance of bacterial genera were mainly Acinetobacter, Pseudomonas, Prevotella and Lactobacillus in all groups (Fig 5). In general, compared to the control group, genus Acinetobacter and Pseudomonas, which both belong to the phylum Proteobacteria, and generally contain many opportunistic pathogenic species, moderately increased in the GDM groups. The genus Prevotella, which is affiliated with the phylum Bacteroidetes, was significantly decreased (P<0.05) in the GDM_A1 group compared to the control group, while the GDM_A2 group had almost no variation. The relative abundance of Lactobacillus within the phylum Firmicutes, which is known as a group of major probiotics, was significantly decreased (P<0.05) in the GDM_A1 group compared to the control group. The relative abundance of Lactobacillus in the GDM_A2 group seemingly increased, however, the increase did not show any statistical difference between the two groups (P>0.05).
The difference of unique gut microbiota between the control and GDM groups
At each taxonomic level, the amount of unique gut microbiota between the control and GDM groups are shown in Fig 6. As was shown in Fig 6A, there were 12 unique bacterial phyla in the control group and 1 unique bacterial phylum in the GDM group, with 38 bacterial phyla common in both groups. According to Fig 6B, at the genus level, a large number of bacterial species in the control group could not be found in the GDM group, and conversely, some unique bacterial species in GDM group couldn’t be found in the control group. In the control group, the number of unique bacterial genera in phyla of Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes, Chloroflexi, Acidobacteria and Planctomycetes were 114, 61, 64, 35, 22, 21 and 20, respectively, which couldn’t be found in GDM group. And in GDM group, the number of the unique bacterial genera in phyla of Proteobacteria, Firmicutes, and Chloroflexi was 8, 5, 2 and 1, respectively, which couldn’t be found in the control group. These unique species may have an association with host metabolism and disease and should be caught on attention. For example, the genus Butyrivibrio has been regarded as a key bacterium in polysaccharide degrading and butyrate producing , however, it was not detected in GDM group.
Correlations between maternal fasting glucose levels and gut microbiota in meconium samples of newborns
To explore whether the maternal glucose metabolism can affect gut microbiota of newborns, correlations between maternal fasting glucose levels and meconium bacteria abundance of newborns were investigated (Fig 7). Results showed that maternal fasting glucose levels were positively correlated with the relative abundance of phylum Actinobacteria (Fig 7A) and genus Acinetobacter (Fig 7C), while maternal fasting glucose were negatively correlated with phylum Bacteroidetes (Fig 7B) and genus Prevotella (Fig 7D). In addition, we also investigated the correlations between maternal clinical index and meconium bacteria abundance of newborns (Figure C in S1 File). There was negative correlation between maternal age and relative abundance of genus Lactobacillus (Figure C in S1A File), while maternal antepartum weight, pre-pregnancy BMI and antepartum BMI were positively correlated with the relative abundance of genus Clostridium (Figure C in S1B, S1C and S1D File).
Spearman’s rank correlation coefficients and P-values for the correlations are shown. (A) Positive correlation between maternal fasting glucose and phylum Actinobacteria (ρ=0.445, P=0.011). (B) Negative correlation between maternal fasting glucose and phylum Bacteroidetes (ρ=-0.414, P=0.018). (C) Positive correlation between maternal fasting glucose and genus Acinetobacter (ρ=0.406, P=0.021). (D) Negative correlation between maternal fasting glucose and genus Prevotella (ρ=-0.393, P=0.026).
In this study, we successfully sequenced 16S rRNA of meconium samples of newborns from mothers with and without GDM, using the high-throughput sequencing platform. Based on the results of species diversity and taxonomy, we confirm that neonatal meconium was rich in bacteria, regardless of whether the mother was suffering from GDM. Moreover, we demonstrated that gut microbiota from GDM newborns showed a great difference to those from control newborns, with the overall microbiome diversity being significantly lower than that of control newborns (Figs 1 and 2). While at the phylum, class, order, family, and genus level, the amount or relative abundance of gut microbiota from GDM newborns also substantially differed from those from control newborns. In addition, our results showed a positive correlation of maternal fasting glucose with the phylum Actinobacteria and genus Acinetobacter, and a negative correlation of maternal fasting glucose with the phylum Bacteroidetes and genus Prevotella.
Gut dysbacteriosis not only induces a variety of gastrointestinal diseases, like diarrhoea, constipation and chronic enteritis, but also contributes to the onset and development of many metabolic syndromes and neurogenic diseases, including obesity , type 2 diabetes mellitus , hypertension  and autism . In the present study, we observed a significant decrease in the diversity of various bacterial types of GDM newborns compared to those of normal newborns. These results are consistent with previous findings suggesting that the gut microbiota in the GDM group was associated with lower alpha-diversity compared to healthy groups . The results from the Weighted UniFrac diversity analysis and PCoA (Fig 2) are also consistent with the decreased alpha-diversity, shown in Fig 1. Regarding the species taxonomy, at the phylum level, bacteria belonging to the phyla of Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes were the first four major gut microbiota in all samples, with the phylum of Proteobacteria being the most abundant of gut microbiota with more than 45% of the total abundance (Fig 4). These results are consistent with the previous findings that the phyla of Actinobacteria, Bacteroidetes, Firmicutes and Proteobacteria were accounted for about 99% of the microbial content in all 23 meconium samples analysed . Furthermore, we observed the phyla of Proteobacteria and Actinobacteria in GDM newborns increased, while the phyla of Firmicutes, Bacteroidetes, Synergistetes, Thermi, Spirochaetes, Chloroflexi, and Euryarchaeota were reduced compared with control infants (Fig 4). It has been well documented that the phylum of Proteobacteria increased in diabetes and obesity, while the phylum of Bacteroidetes decreased [35, 36]. In addition, the amount of a number of bacteria at the level of class, order and family in the GDM group decreased significantly (Figure B in S1 File). Moreover, a large number of unique gut microbiota in the phyla of Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes, Chloroflexi, Acidobacteria and Planctomycetes from control newborns were absent in GDM newborns. These results indicate that there might be serious dysbacteriosis in the gut of GDM newborns, and they could potentially more prone to suffer from gastrointestinal diseases and metabolic syndrome at subsequent stages in their lives. Clausen et al. have also shown that adult offspring of women with diet-treated GDM or type 1 diabetes are at risk for being overweight and developing metabolic syndromes .
Several studies suggest that hyperglycaemia caused by GDM could affect the metabolism of the intrauterine foetus, thus greatly increasing the risk of metabolic syndrome development [38, 39]. Progression of glucose intolerance is accompanied by changes in the proportion and diversity of the gut microbiota . Recently, it was reported that type 2 diabetes in humans was associated with a reduced abundance of butyrate-producing bacteria , the decreased levels of which may contribute to diseases . Murri et al. reported a significant decrease in the number of Lactobacillus and Prevotella in children with diabetes . In the present study, we also observed the relative abundance of Prevotella and Lactobacillus significantly decreased in GDM newborns (Fig 6). Correlation analysis indicated that maternal fasting glucose levels were negatively correlated with the relative abundance of phylum Bacteroidetes (Fig 7B) and genus Prevotella (Fig 7D). Lactobacillus has members with probiotic characteristics, which have been associated with positive effects for the host in the large intestine . In addition, many beneficial organic acid lactates produced by Lactobacillus could be converted into butyrate by butyrate-producing bacteria in the gut . Previous studies have highlighted the physiological functions of Prevotella in maintaining the community structure of human gut microbiome [45, 46]. In addition, another study reported that autism-related gastrointestinal disorders may be linked to the absence of Prevotella, especially the P. copri -like phylotype . Consequently, we speculated that variation of these genera of gut bacteria might be related to diabetes and gastrointestinal disorders, which may pose GDM newborns at a higher risk of developing these diseases in the future than control newborns. It is worth noting that the genera of Prevotella and Lactobacillus from the GDM_A2 group did not show any statistical variation compared to those from the control group. We speculate that the pregnant women with GDM grade A2 were additionally treated by insulin, which might have affected the gut microbiota of those mothers.
Nevertheless, the impact of GDM treatments and antibiotics contributing to neonatal microbiota need to be further investigated. The maternal treatments might affect infant microbiota, as some researchers have previously described. More molecular sequencing technologies are also recommended for microbe species investigation apart from 16S rRNA sequencing. Likewise, it is suggested to conduct more experiments using RNA sequencing and Metabolomics to investigate how GDM may influence the growth and metabolism of GDM mothers and newborns. In our study, another limitation includes the fact that the sample size may not have allowed us to detect modest differences in bacterial distribution. Therefore, a larger sample size and a functional analysis will also be needed in future studies. Furthermore, may be worth comparing the microbiota of infants and GDM mothers after different treatments of GDM sub-groups.
A previous study has shown that the microbial connection between infant and mother starts before birth, with specific bacteria or bacterial components already observed in utero . A rapid emergence of different gut microbiota in the infant occurs shortly after delivery. This stepwise microbiota transfer is expected to be controlled, but it is also affected by external factors, such as weaning, diet habits and environmental exposures to microbes. Several studies have reported that the maternal health status would influence the transfer of microbiota to their offspring [34, 49]. The intestinal microbial community appears to be vulnerable to perturbations during the early life-stages of newborns and it also has fundamental effects on the development of the host immune system . According to our results, the gut microbiota in GDM newborns was significantly different from control newborns. Hence, it is reasonable to assume that regulating the gut microbiota of pregnant women could be a potential path to prevent GDM and decrease the risk of childhood obesity, as well as type 2 diabetes. It has shown that interventions, such as antibiotic treatment or exposure to antibiotics repeatedly, can influence the composition of gut microbiota . Likewise, a certain number of studies have also shown that probiotic supplements are beneficial in the prevention of GDM [52, 53]. However, the evidence for the utilization of antibiotics and probiotics in diagnosed GDM is still scanty and remains to be elucidated.
In conclusion, it has been established that the gut microbiota is an important factor in the onset and development of metabolic diseases . Nevertheless, the specific microbiome components promoting or protecting against these metabolic syndromes and the possible molecular targets of interventions are still under debate. The future of therapeutic potential on the gut microbiota remains to be demonstrated. At present, there is significant ongoing research on microbiome-based therapeutics for gut microbiota worldwide. Fecal microbiota transplant (FMT) has been proven to be effective in treating refractory Clostridium difficile infections . Butyrate-producing bacteria preferentially ferment dietary fibers into butyrate and other short chain fatty acids in the colon [55, 56], which are beneficial to the host. It has been reported that butyrate improves insulin resistance and fasting hyperglycaemia by inhibiting adipocyte inflammation [57, 58]. We anticipate that the results of this study may have important implications for understanding the onset, development and optimal treatment of GDM-related diseases by taking effective preventive measures. Investigating the relationship between GDM mother’s and newborn’s gut microbiota could potentially provide more insight on the mechanisms of gut dysbacteriosis.
File includes Figure A, B, and C. Figure A. Rarefaction curve. Number of observed species identified with increase of sequencing depth in meconium samples of newborns. Figure B. Comparison of the amount of gut microbiota at bacterial taxonomic levels between GDM and control group in the main phyla. (A) Class level. (B) Order level. (C) Family level. The P-values were calculated using Mann-Whitney test, and significance was compared against the control group. *P < 0.05. Figure C. Correlations between maternal clinical index and gut microbiota in meconium samples of newborns. Spearman’s rank correlation coefficients and P-values for the correlations are shown. (A) Negative correlation between maternal age and genus Lactobacillus (ρ=-0.344, P=0.047). (B) Positive correlation between maternal antepartum weight and genus Clostridium (ρ=0.450, P=0.009). (C) Positive correlation between maternal pre-pregnancy BMI and genus Clostridium (ρ=0.551, P=0.001). (D) Positive correlation between maternal antepartum BMI and genus Clostridium (ρ=0.433, P=0.012).
We thank all the patients and other volunteers to provide the samples for the current work.
- 1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012; 35 Suppl 1:S64–S71. https://doi.org/10.2337/dc12-s064 pmid:22187472
- 2. Law KP, Zhang H. The pathogenesis and pathophysiology of gestational diabetes mellitus: Deductions from a three-part longitudinal metabolomics study in China. Clin Chim Acta. 2017; 468:60–70. https://doi.org/10.1016/j.cca.2017.02.008 pmid:28213010
- 3. Zhang F, Dong L, Zhang CP, Li B, Wen J, Gao W, et al. Increasing prevalence of gestational diabetes mellitus in Chinese women from 1999 to 2008. Diabet Med. 2011; 28:652–657. https://doi.org/10.1111/j.1464-5491.2010.03205.x pmid:21569085
- 4. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008; 358:1991–2002. https://doi.org/10.1056/NEJMoa0707943 pmid:18463375
- 5. Shah BR, Retnakaran R, Booth GL. Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. Diabetes Care. 2008; 31:1668–1669. https://doi.org/10.2337/dc08-0706 18487472 pmid:18487472
- 6. American Diabetes Association. Standards of medical care in diabetes--2018. Diabetes Care. 2018; 41(Suppl 1):S152–S153. https://doi.org/10.2337/dc18-S015 pmid:29222386
- 7. Mitanchez D. Foetal and neonatal complications in gestational diabetes: perinatal mortality, congenital malformations, macrosomia, shoulder dystocia, birth injuries, neonatal complications. Diabetes Metab. 2010; 36:617–627. https://doi.org/10.1016/j.diabet.2010.11.013 pmid:21163425
- 8. Gillman MW, Rifas-Shiman S, Berkey CS, Field AE, Colditz GA. Maternal gestational diabetes, birth weight, and adolescent obesity. Pediatrics. 2003; 111:221–226. https://doi.org/10.1542/peds.111.3.e221 PMID: 12509584
- 9. Ornoy A, Wolf A, Ratzon N, Greenbaum C, Dulitzky M. Neurodevelopmental outcome at early school age of children born to mothers with gestational diabetes. Arch Dis Child Fetal Neonatal Ed. 1999; 81:10–14. https://doi.org/10.1136/fn.81.1.F10 pmid:10375355
- 10. Dionne G, Boivin M, Séguin JR, Pérusse D, Tremblay RE. Gestational diabetes hinders language development in offspring. Pediatrics. 2008; 122:1073–1079. https://doi.org/10.1542/peds.2007-3028 pmid:18977957
- 11. Satokari R, Grönroos T, Laitinen K, Salminen S, Isolauri E. Bifidobacterium and Lactobacillus DNA in the human placenta. Lett Appl Microbiol. 2009; 48:8–12. https://doi.org/10.1111/j.1472-765X.2008.02475.x pmid:19018955
- 12. Gritz EC, Bhandari V. Corrigendum: The human neonatal gut microbiome: a brief review. Front Pediatr. 2015; 3:60. https://doi.org/10.3389/fped.2015.00060 pmid:26176006
- 13. Geva-Zatorsky N, Sefik E, Kua L, Pasman L, Tan TG, Ortiz-Lopez A, et al. Mining the human gut microbiota for immunomodulatory organisms. Cell. 2017; 168:928–943. https://doi.org/10.1016/j.cell.2017.01.022 pmid:28215708
- 14. Arrieta MC, Stiemsma LT, Dimitriu PA, Thorson L, Russell S, Yurist-Doutsch S, et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci Transl Med. 2015; 7:307ra152. https://doi.org/10.1126/scitranslmed.aab2271 pmid:26424567
- 15. Li HT, Zhou YB, Liu JM. The impact of cesarean section on offspring overweight and obesity: a systematic review and meta-analysis. Int J Obes. 2013; 37:893–899. https://doi.org/10.1038/ijo.2012.195 pmid:23207407
- 16. Darmasseelane K, Hyde MJ, Santhakumaran S, Gale C, Modi N. Mode of delivery and offspring body mass index, overweight and obesity in adult life: a systematic review and meta-analysis. Plos One. 2014; 9:e87896. https://doi.org/10.1371/journal.pone.0087896 pmid:24586295
- 17. Kuhle S, Tong OS, Woolcott CG. Association between caesarean section and childhood obesity: a systematic review and meta-analysis. Obes Rev. 2015; 16:295–303. https://doi.org/10.1111/obr.12267 pmid:25752886
- 18. Biasucci G, Benenati B, Morelli L, Bessi E, Boehm G. Cesarean delivery may affect the early biodiversity of intestinal bacteria. J Nutr. 2008; 138:1796S–1800S. https://doi.org/10.1093/jn/138.9.1796S pmid:18716189
- 19. Jiménez E, Marín ML, Martín R, Odriozola JM, Olivares M, Xaus J, et al. Is meconium from healthy newborns actually sterile? Res Microbiol. 2008; 159:187–193. https://doi.org/10.1016/j.resmic.2007.12.007 pmid:18281199
- 20. Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J. The placenta harbors a unique microbiome. Sci Transl Med. 2014; 6:237ra65. https://doi.org/10.1126/scitranslmed.3008599 pmid:24848255
- 21. Kuang YS, Lu JH, Li SH, Li JH, Yuan MY, He JR, et al. Connections between the human gut microbiome and gestational diabetes mellitus. Gigascience. 2017; 6:1–12. https://doi.org/10.1093/gigascience/gix058 pmid:28873967
- 22. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ, et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci U S A. 2011; 108 Suppl 1:4516–4522. https://doi.org/10.1073/pnas.1000080107 pmid:20534432
- 23. Price MN, Dehal PS, Arkin AP. FastTree: Computing large minimum evolution trees with profiles instead of a distance matrix. Mol Biol Evol. 2009; 26:1641–1650. https://doi.org/10.1093/molbev/msp077 pmid:19377059
- 24. Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005; 71:8228–8235. https://doi.org/10.1128/AEM.71.12.8228-8235.2005 pmid:16332807
- 25. Lozupone CA, Hamady M, Kelley ST, Knight R. Quantitative and qualitative β diversity measures lead to different insights into factors that structure microbial communities. Appl Environ Microbiol. 2007; 73:1576–1585. https://doi.org/10.1128/AEM.01996-06 pmid:17220268
- 26. International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010; 33:676–682. https://doi.org/10.2337/dc09-1848 pmid:20190296
- 27. White P. Pregnancy complicating diabetes. Am J Med. 1949; 7:609–616. https://doi.org/10.1016/0002-9343(49)90382-4 pmid:15396063
- 28. Luo M, Liu Y, Wu P, Luo DX, Sun Q, Zheng H, et al. Alternation of gut microbiota in patients with pulmonary tuberculosis. Front Physiol. 2017; 8:822. https://doi.org/10.3389/fphys.2017.00822 pmid:29204120
- 29. Dunne JC, Kelly WJ, Leahy SC, Li D, Bond JJ, Peng L, et al. The cytosolic oligosaccharide-degrading proteome of Butyrivibrio proteoclasticus. Proteomes. 2015; 3:347–368. https://doi.org/10.3390/proteomes3040347 pmid:28248275
- 30. Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, Greve JW, et al. Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. Obesity. 2013; 21:E607–E615. https://doi.org/10.1002/oby.20466 pmid:23526699
- 31. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012; 490:55–60. https://doi.org/10.1038/nature11450 pmid:23023125
- 32. Gomez-Arango LF, Barrett HL, McIntyre HD, Callaway LK, Morrison M, Dekker Nitert M, et al. Increased systolic and diastolic blood pressure is associated with altered gut microbiota composition and butyrate production in early pregnancy. Hypertension. 2016; 68:974–981. https://doi.org/10.1161/HYPERTENSIONAHA.116.07910 pmid:27528065
- 33. Strati F, Cavalieri D, Albanese D, De Felice C, Donati C, Hayek J, et al. New evidences on the altered gut microbiota in autism spectrum disorders. Microbiome. 2017; 5:24. https://doi.org/10.1186/s40168-017-0242-1 pmid:28222761
- 34. Hu J, Nomura Y, Bashir A, Fernandez-Hernandez H, Itzkowitz S, Pei Z, et al. Diversified microbiota of meconium is affected by maternal diabetes status. Plos One. 2013; 8:e78257. https://doi.org/10.1371/journal.pone.0078257 pmid:24223144
- 35. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005; 102:11070–11075. https://doi.org/10.1073/pnas.0504978102 pmid:16033867
- 36. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009; 457:480–484. https://doi.org/10.1038/nature07540 pmid:19043404
- 37. Clausen TD, Mathiesen ER, Hansen T, Pedersen O, Jensen DM, Lauenborg J, et al. Overweight and the metabolic syndrome in adult offspring of women with diet-treated gestational diabetes mellitus or type 1 diabetes. J Clin Endocrinol Metab. 2009; 94:2464–2470. https://doi.org/10.1210/jc.2009-0305 pmid:19417040
- 38. Dabelea D, Hanson RL, Lindsay RS, Pettitt DJ, Imperatore G, Gabir MM, et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes. 2000; 49:2208–2211. https://doi.org/10.2337/diabetes.49.12.2208 pmid:11118027
- 39. Tsadok MA, Friedlander Y, Paltiel O, Manor O, Meiner V, Hochner H, et al. Obesity and blood pressure in 17-year-old offspring of mothers with gestational diabetes: insights from the Jerusalem Perinatal Study. Exp Diabetes Res. 2011; 2011:906154. https://doi.org/10.1155/2011/906154 pmid:21804818
- 40. Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, et al. Human gut microbiota changes reveal the progression of glucose intolerance. Plos One. 2013; 8:e71108. https://doi.org/10.1371/journal.pone.0071108 pmid:24013136
- 41. Vrieze A, Out C, Fuentes S, Jonker L, Reuling I, Kootte RS, et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol. 2014; 60:824–831. https://doi.org/10.1016/j.jhep.2013.11.034 pmid:24316517
- 42. Murri M, Leiva I, Gomez-Zumaquero JM, Tinahones FJ, Cardona F, Soriguer F, et al. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Med. 2013; 11:46. https://doi.org/10.1186/1741-7015-11-46 pmid:23433344
- 43. Tzounis X, Rodriguez-Mateos A, Vulevic J, Gibson GR, Kwik-Uribe C, Spencer JP. Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. Am J Clin Nutr. 2011; 93:62–72. https://doi.org/10.3945/ajcn.110.000075 pmid:21068351
- 44. Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, Mukherjee N, et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One. 2011; 6:e25792. https://doi.org/10.1371/journal.pone.0025792 pmid:22043294
- 45. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011; 473:174–180. https://doi.org/10.1038/nature09944 pmid:21508958
- 46. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. Nature. 2012; 486:222–227. https://doi.org/10.1038/nature11053 pmid:22699611
- 47. Kang DW, Park JG, Ilhan ZE, Wallstrom G, Labaer J, Adams JB, et al. Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. Plos One. 2013; 8:e68322. https://doi.org/10.1371/journal.pone.0068322 pmid:23844187
- 48. Isolauri E, Rautava S, Collado MC, Salminen S. Role of probiotics in reducing the risk of gestational diabetes. Diabetes Obes Metab. 2015; 17:713–719. https://doi.org/10.1111/dom.12475 pmid:25885278
- 49. Cabrera-Rubio R, Collado MC, Laitinen K, Salminen S, Isolauri E, Mira A. The human milk microbiome changes over lactation and is shaped by maternal weight and mode of delivery. Am J Clin Nutr. 2012; 96:544–551. https://doi.org/10.3945/ajcn.112.037382 pmid:22836031
- 50. Kerr CA, Grice DM, Tran CD, Bauer DC, Li D, Hendry P, et al. Early life events influence whole-of-life metabolic health via gut microflora and gut permeability. Crit Rev Microbiol. 2015; 41:326–340. https://doi.org/10.3109/1040841X.2013.837863 pmid:24645635
- 51. Barrett HL, Dekker Nitert M, Conwell LS, Callaway LK. Probiotics for preventing gestational diabetes. Cochrane Database Syst Rev. 2014; (2):CD009951. https://doi.org/10.1002/14651858.CD009951.pub2 pmid:24574258
- 52. Lindsay KL, Walsh CA, Brennan L, McAuliffe FM. Probiotics in pregnancy and maternal outcomes: a systematic review. J Matern Fetal Neonatal Med. 2013; 26:772–778. https://doi.org/10.3109/14767058.2012.755166 pmid:23205866
- 53. Dolatkhah N, Hajifaraji M, Abbasalizadeh F, Aghamohammadzadeh N, Mehrabi Y, Abbasi MM. Is there a value for probiotic supplements in gestational diabetes mellitus? A randomized clinical trial. J Health Popul Nutr. 2015; 33:25. https://doi.org/10.1186/s41043-015-0034-9 pmid:26825666
- 54. Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection a randomized trial. Ann Intern Med. 2016; 165:609–616. https://doi.org/10.7326/M16-0271 pmid:27547925
- 55. Endo H, Niioka M, Kobayashi N, Tanaka M, Watanabe T. Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis. Plos One. 2013; 8:e63388. https://doi.org/10.1371/journal.pone.0063388 pmid:23696823
- 56. Nylund L, Nermes M, Isolauri E, Salminen S, de Vos WM, Satokari R. Severity of atopic disease inversely correlates with intestinal microbiota diversity and butyrate-producing bacteria. Allergy. 2015; 70:241–244. https://doi.org/10.1111/all.12549 pmid:25413686
- 57. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes. 2009; 58:1509–1517. https://doi.org/10.2337/db08-1637 pmid:19366864
- 58. Wang X, He G, Peng Y, Zhong W, Wang Y, Zhang B. Sodium butyrate alleviates adipocyte inflammation by inhibiting NLRP3 pathway. Scientific Reports. 2015; 5:12676. https://doi.org/10.1038/srep12676 pmid:26234821